Payment overview · 2025
General Payments
$623.08
19 reported records · 9 companies
Healthcare provider profile · identity verified
Jaclynn J Do, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GARDEN GROVE, CA · NPI 1366439051
Verified facts
What the public records show
CMS Open Payments records show Jaclynn J Do, M.D. received $623.08 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Otezla, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 211 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $141.61 | 22.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.09 | 22.5% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $101.06 | 16.2% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $79.76 | 12.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $47.00 | 7.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $42.51 | 6.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $28.66 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.60 | 3.5% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $20.79 | 3.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $623.08 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $141.69 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $119.93 | 4 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $101.06 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $79.76 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $77.40 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $47.00 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $42.51 | 2 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 211 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
211 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
106 | 18 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 389 | 131 |
| Lovastatin | Lovastatin | 344 | 105 |
| Losartan Potassium | Losartan Potassium | 307 | 107 |
| Metformin Hcl | Metformin Hcl | 281 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 87 |
| Jardiance | Empagliflozin | 211 | 43 |
| Benazepril Hcl | Benazepril Hcl | 210 | 66 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 56 |
| Meloxicam | Meloxicam | 178 | 65 |
| Alendronate Sodium | Alendronate Sodium | 177 | 73 |
| Gabapentin | Gabapentin | 148 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 145 | 47 |
| Omeprazole | Omeprazole | 126 | 29 |
| Famotidine | Famotidine | 122 | 43 |
| Trulicity | Dulaglutide | 106 | 18 |
| Lisinopril | Lisinopril | 105 | 31 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 25 |
| Glipizide | Glipizide | 90 | 24 |
| Tradjenta | Linagliptin | 85 | 12 |
| Levothyroxine Sodium | Levothyroxine Sodium | 83 | 25 |
| Januvia | Sitagliptin Phosphate | 78 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 69 | 24 |
| Vascepa | Icosapent Ethyl | 67 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 27 |
| Atenolol | Atenolol | 58 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 53 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 49 | 17 |
| Irbesartan | Irbesartan | 48 | 13 |
| Metformin Hcl Er | Metformin Hcl | 48 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 46 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 44 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 42 | 12 |
| Ezetimibe | Ezetimibe | 41 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 12 |
| Naproxen | Naproxen | 38 | 22 |
| Ibuprofen | Ibuprofen | 37 | 30 |
| Simvastatin | Simvastatin | 37 | 12 |
| Carvedilol | Carvedilol | 35 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 33 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Donepezil Hcl | Donepezil Hcl | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 29 | 16 |
| Restasis | Cyclosporine | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 25 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 21 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 20 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 19 | suppressed |
| Alprazolam | Alprazolam | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Loperamide | Loperamide Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 16 |
| Valsartan | Valsartan | 17 | suppressed |
| Eliquis | Apixaban | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 15 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Linzess | Linaclotide | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 14 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $623.08 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEXSERO, BREZTRI, CAPVAXIVE, Dexcom G6 Transmitter, GARDASIL 9, JARDIANCE, M-M-R II, MOUNJARO, OTEZLA, PENMENVY, REPATHA, TREMFYA, VAXELIS, VAXNEUVANCE, ZENPEP, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error